XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenue $ 46,333 $ 40,134 $ 152,877 $ 120,614
License Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 0 2,649 0 9,649
Development Revenue [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 385 6,775 1,532 15,825
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 382 2,322 987 5,657
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue 0 2,649 0 2,649
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0 $ 3,676 $ 418 $ 7,981